These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25084172)

  • 21. Intravenous immunoglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis--the Israeli experience. MS Study Group.
    Achiron A; Rotstein Z; Barak Y; Sarova-Pinhas I
    Mult Scler; 1997 Apr; 3(2):142-4. PubMed ID: 9291169
    [No Abstract]   [Full Text] [Related]  

  • 22. Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely.
    Baker D; Amor S
    Mult Scler Relat Disord; 2014 Sep; 3(5):555-64. PubMed ID: 26265267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reglation of neuroinflammation.
    Willenborg DO; Staykova M
    J Neuroimmunol; 2007 Nov; 191(1-2):1. PubMed ID: 17942161
    [No Abstract]   [Full Text] [Related]  

  • 24. Concerning: "The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy" by Peter O. Behan and Abhijit Chaudhuri.
    Upton AR
    Inflammopharmacology; 2010 Dec; 18(6):263. PubMed ID: 21046469
    [No Abstract]   [Full Text] [Related]  

  • 25. Paradox of B cell-targeted therapies.
    Kurosaki T
    J Clin Invest; 2008 Oct; 118(10):3260-3. PubMed ID: 18802484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of immunologic nervous system diseases by using anti-adhesion molecule antibodies].
    Kawai K; Sobue G
    Nihon Naika Gakkai Zasshi; 1998 Apr; 87(4):691-6. PubMed ID: 9627479
    [No Abstract]   [Full Text] [Related]  

  • 27. Type 1 interferons cool the inflamed brain.
    Axtell RC; Steinman L
    Immunity; 2008 May; 28(5):600-2. PubMed ID: 18482563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transduced B cells: B is for 'beneficial'!
    Scott DW
    Eur J Immunol; 2011 Jun; 41(6):1528-30. PubMed ID: 21618505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the evidence for multiple sclerosis as an autoimmune disease.
    Altmann D
    Arch Neurol; 2005 Apr; 62(4):688; author reply 688-9. PubMed ID: 15824275
    [No Abstract]   [Full Text] [Related]  

  • 30. T cell design for therapy in autoimmune demyelinating disease.
    Tuohy VK; Mathisen PM
    J Neuroimmunol; 2000 Jul; 107(2):226-32. PubMed ID: 10854661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Janus faces of amyloid proteins in neuroinflammation.
    Steinman L; Rothbard JB; Kurnellas MP
    J Clin Immunol; 2014 Jul; 34 Suppl 1(Suppl 1):S61-3. PubMed ID: 24711007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Multiple sclerosis and experimental autoimmune encephalomyelitis].
    Béraud-Juven E
    Rev Prat; 1994 Jan; 44(1):69-74. PubMed ID: 8178062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is T-bet a potential therapeutic target in multiple sclerosis?
    Racke MK; Yang Y; Lovett-Racke AE
    J Interferon Cytokine Res; 2014 Aug; 34(8):623-32. PubMed ID: 25084179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicine: Collateral damage repaired.
    Steinman L
    Nature; 2003 Apr; 422(6933):671-2. PubMed ID: 12700743
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunological studies in experimental allergic encephalomyelitis and in multiple sclerosis with special reference to pathogenesis and diagnosis.
    Lamoureux G
    Proc Aust Assoc Neurol; 1966; 4():125-32. PubMed ID: 4165114
    [No Abstract]   [Full Text] [Related]  

  • 36. Cell-based modulation of autoimmune responses in multiple sclerosis and experimental autoimmmune encephalomyelitis: therapeutic implications.
    Mastorodemos V; Ioannou M; Verginis P
    Neuroimmunomodulation; 2015; 22(3):181-95. PubMed ID: 24852748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of multiple sclerosis.
    Br Med J; 1980 Jan; 280(6207):65-6. PubMed ID: 6766340
    [No Abstract]   [Full Text] [Related]  

  • 38. Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development.
    Rolla S; Ingoglia G; Bardina V; Silengo L; Altruda F; Novelli F; Tolosano E
    J Immunol; 2013 Dec; 191(11):5451-9. PubMed ID: 24154625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting.
    Stinissen P; Raus J
    Acta Neurol Belg; 1999 Mar; 99(1):65-9. PubMed ID: 10218096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system.
    Larochelle C; Cayrol R; Kebir H; Alvarez JI; Lécuyer MA; Ifergan I; Viel É; Bourbonnière L; Beauseigle D; Terouz S; Hachehouche L; Gendron S; Poirier J; Jobin C; Duquette P; Flanagan K; Yednock T; Arbour N; Prat A
    Brain; 2012 Oct; 135(Pt 10):2906-24. PubMed ID: 22975388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.